SomnoMed Ltd
Company Profile
Business description
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
Contact
20 Clarke Street
Level 3
Crows Nest
SydneyNSW2065
AUST: +61 294670400
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2027
Employees
22
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,338.81 | 39.05 | -0.47% |
| DAX 40 | 24,830.98 | 84.51 | -0.34% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,600.37 | 28.13 | 0.27% |
| HKSE | 24,562.24 | 446.36 | -1.78% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.15 | 118.26 | -3.05% |